$2.91
2.11% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US68403P2039
Symbol
ORMP

Oramed Pharmaceuticals Inc. Stock price

$2.91
+0.16 5.82% 1M
+0.75 34.72% 6M
+0.06 2.11% YTD
+0.50 20.75% 1Y
-9.12 75.81% 3Y
-1.44 33.10% 5Y
-5.58 65.72% 10Y
-0.81 21.77% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+0.06 2.11%
ISIN
US68403P2039
Symbol
ORMP
Industry

Key metrics

Basic
Market capitalization
$115.8m
Enterprise Value
$-18.9m
Net debt
positive
Cash
$134.7m
Shares outstanding
40.8m
Valuation (TTM | estimate)
P/E
2.9 | 2.2
P/S
57.9 | 56.8
EV/Sales
negative | negative
EV/FCF
1.8
P/B
0.6
Financial Health
Equity Ratio
94.2%
Return on Equity
-13.0%
ROCE
-6.1%
ROIC
-12.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$2.0m | $2.0m
EBITDA
$-12.9m | -
EBIT
$-13.0m | $-12.6m
Net Income
$43.9m | $53.3m
Free Cash Flow
$-10.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-0.3% | -
EBIT
0.4% | 1.0%
Net Income
881.0% | 379.8%
Free Cash Flow
-33.8%
Margin (TTM | estimate)
Gross
0.7%
EBITDA
-644.5% | -
EBIT
-650.6%
Net
2,192.6% | 2,613.8%
Free Cash Flow
-530.4%
More
EPS
$1.0
FCF per Share
$-0.3
Short interest
0.9%
Employees
4
Rev per Employee
$0.0
Show more

Is Oramed Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Oramed Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Oramed Pharmaceuticals Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Oramed Pharmaceuticals Inc. forecast:

Hold
50%
Sell
50%

Financial data from Oramed Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
2 2
-
100%
- Direct Costs 1.99 1.99
-
100%
0.01 0.01
-
1%
- Selling and Administrative Expenses 7.17 7.17
12% 12%
359%
- Research and Development Expense 5.85 5.85
12% 12%
293%
-13 -13
0% 0%
-645%
- Depreciation and Amortization 0.12 0.12
45% 45%
6%
EBIT (Operating Income) EBIT -13 -13
0% 0%
-651%
Net Profit 44 44
881% 881%
2,193%

In millions USD.

Don't miss a Thing! We will send you all news about Oramed Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Oramed Pharmaceuticals Inc. Stock News

Neutral
Seeking Alpha
10 days ago
Oramed remains viable after its flagship product failed FDA trials three years ago. Management identified a responsive patient subset—elderly with low BMI and high baseline HbA1c—prompting a new 60-patient trial. Positive results from ORMP's Chinese partner reinforce the potential for this narrower patient group.
Neutral
PRNewsWire
about 2 months ago
Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million NEW YORK , Nov. 17, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, today announced its unaudited financial results for the nine months ...
Neutral
PRNewsWire
about 2 months ago
NEW YORK , Nov. 17, 2025 /PRNewswire/ -- The Board of Directors of Oramed Pharmaceuticals Inc. (the "Company") announced today that it has unanimously adopted a Rights Agreement, dated November 17, 2025 (the "Rights Plan"), by and between the Company and Continental Stock Transfer & Trust Company, as rights agent, and declared a dividend of one common stock purchase right (a "Right") on each ou...
More Oramed Pharmaceuticals Inc. News

Company Profile

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in Jerusalem, Israel.

Head office United States
CEO Nadav Kidron
Employees 4
Founded 2002
Website oramed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today